Reported 29 days ago
Genetic sequencing company Illumina has faced significant challenges, including stock declines and regulatory issues, compounded by a recent settlement over a cybersecurity breach. CEO Jacob Thaysen remains optimistic, citing potential collaborations with pharmaceutical companies to leverage patient data for drug development and cancer care. Despite setbacks in China due to geopolitical tensions and local competition, Thaysen believes the oncology business will see growth in the coming years, although analysts urge caution until clearer trends emerge.
Source: YAHOO